Cancer remains one of our greatest and growing healthcare challenges.1 Globally, it is estimated that 17 million new cancer cases occurred in 2018, with 9.6 million deaths and by 2040, the global burden is expected to grow to 27.5 million new cancer cases as a result of a growing and ageing population.2
But cancer isn’t a single disease. There are now more than 100 types of cancer and its biology is constantly changing, making it one of the most complex diseases to treat.3
Pfizer is developing treatments that are as diverse as the disease itself. Whilst traditional cancer-fighting tools like chemotherapy and radiation remain important treatment options for patients and doctors, our scientists are working to uncover new approaches to attack cancer cells directly and more effectively. With a focus on the most disruptive advances in science and guided by the urgency to help patients receive the next wave of life-changing cancer medicines, we hope to develop ever more targeted and sophisticated treatments that have the real potential to transform patients’ lives.
Pfizer is proud of our long-standing support of the Science Museum Group.
The latest developments in oncology and medicine are getting to grips with the evolutionary nature of cancer.
'Breakthrough Nation II' provides our latest thinking for how industry and government can work better together.